Drug intelligence / Profile preview

Adapinoid

Development stage: Unknown
Lead developer: Actera Ingredients
Modality: Small Molecules
Administration: Topical

Overview

Adapinoid, also known as Oleyl Adapalenate, is a novel third-generation retinoid and a prodrug of adapalene. It is being investigated for its effects on facial skin health, appearance, and tolerability, particularly in the treatment of photoaging. Clinical trials have shown that topical Adapinoid 0.5% is superior to retinol 0.5% in improving wrinkle severity and comparable in improving pigment intensity, while also being better tolerated.

Brand names: Adapinoid
Other names: Oleyl Adapalenate

Targets

RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)

Beyond the preview

Go deeper on Adapinoid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adapinoid.

Explore the full profile